Table 1.
Recent Phase I/II, II, III and/or IV clinical trials for approved PARP inhibitors: monotherapy and combination therapy
| Target | Agent | Intervention | Cancer type | Phase | Clinicaltrials.gov identifier |
|---|---|---|---|---|---|
| PARP | Olaparib | Olaparib | BRCA1/2m CRPC | IV | NCT05457257 |
| Optimal dosing of oral anticancer drugs (e.g., Olaparib) | Renal cell, ovarian, thyroid, breast and endometrial carcinoma | IV | NCT05949424 | ||
| Olaparib | Breast and ovarian cancer | IV | NCT04330040 | ||
| Olaparib (adjuvant) | HER2- BRCA1/2m breast cancer | III | NCT02032823 | ||
| Olaparib | HRD-mCRPC | III | NCT02987543 | ||
| Olaparib + Abiraterone | mCRPC | III | NCT03732820 | ||
| Olaparib (MT) | Ovarian cancer | III | |||
| Olaparib + Bevacizumab | Ovarian, fallopian tube or peritoneal cancer | III | NCT02477644 | ||
| Olaparib + Durvalumab | Proficient-MMR endometrial cancer | III | NCT04269200 | ||
| Olaparib + Alpelisib | PtR ovarian cancer | III | NCT04729387 | ||
| Niraparib | Niraparib (MT) | Ovarian cancer | IV | NCT05187208 NCT06412120 NCT03752216 NCT04861181 | |
| Niraparib (MT) | PtS ovarian cancer | III | NCT02655016 NCT01847274 NCT03705156 NCT03709316 | ||
| Niraparib vs Placebo | HER2- BRCA1/2m breast cancer or TNBC | III | NCT04915755 | ||
| RT vs Brachytherapy (vaginal) vs Observation vs Niraparib | Serous or TP53-mutated endometrial cancer | III | NCT04159155 | ||
| Niraparib or Temozolomide | Glioblastoma | III | NCT06388733 | ||
| Abiraterone + Prednisone ± Niraparib | HRD-CRPC | III | NCT04497844 NCT03748641 | ||
| Niraparib + CTx ± Bevacizumab | Ovarian cancer | III | NCT05009082 | ||
| Niraparib ± Pembrolizumab (MT) | NSCLC | III | NCT04475939 | ||
| Niraparib ± Dostarlimab vs CTx | Endometrial or ovarian carcinosarcoma | II/III | NCT03651206 | ||
| Niraparib + Dostarlimab vs CTx | Ovarian, fallopian tube or peritoneal cancer | III | NCT04679064 | ||
| SOC ± Niraparib ± Dostarlimab | Ovarian cancer | III | NCT03602859 | ||
| Carboplatin-Paclitaxel + Dostarlimab/Placebo ± Niraparib | Endometrial cancer | III | NCT03981796 | ||
| CTx + Niraparib ± Atezolizumab | Ovarian cancer | III | NCT03598270 | ||
| Molecular targeted therapy (e.g., Niraparib) vs CTx | Biliary cancer | III | NCT05615818 | ||
| Niraparib + Heated Intraperitoneal CTx | Ovarian, fallopian tube or peritoneal cancer | III | NCT05659381 | ||
| SOC vs SOC+3 treatments (SBRT, radioactive material or Niraparib) | Castration-sensitive prostate cancer | III | NCT06320067 | ||
| Biomarker-driven therapy (e.g., Niraparib + Abiraterone + Prednisone) vs SOC | Metastatic prostate cancer | III | NCT03903835 | ||
| Atezolizumab + other (e.g., Niraparib) | Rollover study | III | NCT03768063 | ||
| Rucaparib | Rucaparib (MT) | Rollover study | III | NCT04676334 | |
| Rucaparib (MT) | PtS ovarian, fallopian tube or peritoneal cancer | III | NCT01968213 | ||
| Rucaparib (MT) post-Bevacizumab | Ovarian, fallopian tube or peritoneal cancer and clear cell carcinoma | III | NCT04227522 | ||
| Rucaparib vs CTx | BRCA1/2m ovarian, fallopian tube or peritoneal cancer | III | NCT02855944 | ||
| Rucaparib vs Abiraterone or Enzalutamide or Docetaxel | HRD-mCRPC | III | NCT02975934 | ||
| Rucaparib + Nivolumab/Placebo (MT) | Ovarian cancer | III | NCT03522246 | ||
| Rucaparib/Placebo + Enzalutamide | mCRPC | III | NCT04455750 | ||
| Atezolizumab + other (e.g., Rucaparib) | Rollover study | III | NCT03768063 | ||
| Talazoparib | Talazoparib vs Capecitabine/Eribulin/Gemcitabine/ Vinorelbine | BRCA1/2m breast cancer | III | NCT01945775 | |
| Talazoparib + Enzalutamide vs Enzalutamide | mCRPC | III | NCT03395197 | ||
| Talazoparib + Enzalutamide vs Placebo | DDR-deficient castration-sensitive prostate cancer | III | NCT04821622 | ||
| Avelumab vs Avelumab + other (e.g., Talazoparib) | Solid tumors | III | NCT05059522 | ||
| Fuzuloparib | Fuzuloparib (MT) | Ovarian cancer | III | NCT03863860 | |
| Fuzuloparib + Abiraterone + Prednisone | CRPC | III | NCT04691804 | ||
| Fuzuloparib/Capecitabine + Camrelizumab | TNBC | III | NCT06533384 | ||
| Fuzuloparib ± Apatinib (MT) | Ovarian cancer | III | NCT06188455 NCT04229615 NCT06539091 | ||
| Fuzuloparib ± Apatinib vs CTx | BRCA1/2m HER2- breast cancer | III | NCT04296370 | ||
| Fuzuloparib + Apatinib vs CTx | HRD/HER2- breast cancer | III | NCT06255392 | ||
| Fuzuloparib + Dalpiciclib + Fulvestrant | HR+/HER2- breast cancer | III | NCT06612814 | ||
| Fuzuloparib + Endocrine therapy | HR+/HER2- SNF3- early breast cancer | III | NCT05891093 | ||
| Pamiparib | Pamiparib (MT) | Ovarian cancer | III | NCT03519230 | |
| Pamiparib + Tislelizumab or Temozolomide | Advanced malignancies | III | NCT04164199 | ||
| Pamiparib | SCLC | II | NCT05483543 | ||
| Pamiparib | Ovarian cancer | II | NCT05489926 | ||
| Pamiparib | HRD-mCRPC | II | NCT05327621 | ||
| Pamiparib | HER2- breast cancer | II | NCT03575065 | ||
| Pamiparib | Gastric cancer | II | NCT03427814 | ||
| Pamiparib | Rare tumors | II | NCT06692491 | ||
| Pamiparib + Surufatinib | Ovarian cancer | II | NCT05652283 | ||
| Pamiparib + Tamoxifen | Ovarian cancer | II | NCT05669768 | ||
| Pamiparib + Tislelizumab | HRD-advanced malignancies | II | NCT04985721 | ||
| Pamiparib + Abiraterone (neoadjuvant) | Prostate cancer | II | NCT05376722 | ||
| Rezvilutamide + Goserelin + Pamiparib | Prostate cancer | II | NCT06387056 | ||
| Pamiparib + Bevacizumab | Ovarian cancer | II | NCT05044871 | ||
| PARPi (e.g., Pamiparib) + Androgen deprivation therapy ± Abiraterone | Prostate cancer | II | NCT05406999 | ||
| Pamiparib | Ovarian cancer and TNBC | I/II | NCT03333915 | ||
| Pamiparib + Surufatinib | Ovarian cancer | I/II | NCT05494580 | ||
| Pamiparib + Temozolomide | IDH1/ 2-mutated gliomas | I/II | NCT03914742 |
Data extracted from clinicaltrials.gov up until November 2025